Birjmohun R S, van der Steeg W A, Stroes E S G, Kastelein J J P
Academisch Medisch Centrum/Universiteit van Amsterdam, afd. Vasculaire Geneeskunde, Meibergdreef 9, 1105, AZ Amsterdam.
Ned Tijdschr Geneeskd. 2006 Oct 14;150(41):2245-50.
The concentration of high-density lipoprotein (HDL) cholesterol has a strong inverse relationship to the incidence of cardiovascular disease. The protective effect of HDL cholesterol is due not only to its promotion of reverse cholesterol transport from the vascular wall to the liver, but also to its anti-inflammatory, antioxidative and antithrombotic effects. Patients with low HDL cholesterol concentrations are at increased risk for cardiovascular disease and may be considered for treatment with lipid-lowering drugs, such as statins, niacin and fibrates. Currently, only a limited number of HDL-increasing agents have demonstrated beneficial effects of increasing HDL in studies with intermediary endpoints. Among these drugs are apolipoprotein A-1 variants, inhibitors of the cholesterol ester transfer protein JTT-705 and torcetrapib.
高密度脂蛋白(HDL)胆固醇的浓度与心血管疾病的发病率呈强烈的负相关。HDL胆固醇的保护作用不仅在于其促进胆固醇从血管壁逆向转运至肝脏,还在于其抗炎、抗氧化和抗血栓形成作用。HDL胆固醇浓度低的患者患心血管疾病的风险增加,可能需要考虑使用降脂药物进行治疗,如他汀类药物、烟酸和贝特类药物。目前,在以中间终点为指标的研究中,仅有有限数量的HDL升高剂显示出升高HDL的有益效果。这些药物包括载脂蛋白A-1变体、胆固醇酯转运蛋白抑制剂JTT-705和托彻普。